CLDN15

Across TCGA pan-cancer cohorts, CLDN15 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CLDN15’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CLDN15 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CLDN15 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LIHC, HNSC, and KICH are the cancer types where CLDN15 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLDN15 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	III,IV	+2.650	<.001	9	view →
HNSC	All	III,IV	+0.605	.001	9	view →
KICH	Female	All	−2.078	<.001	7	view →
KIRC	All	II,III,IV	−0.749	<.001	7	view →
UCEC	All	All	−1.009	<.001	6	view →
BRCA	All	II,III,IV	−0.728	<.001	6	view →
BLCA	Female	All	+0.657	.039	4	view →
READ	Male	All	−1.180	.047	2	view →
STAD	All	II,III,IV	+1.310	.038	1	view →
CHOL	All	All	+0.735	.026	1	view →
LUAD	All	All	−0.298	.014	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CLDN15–LIHC

Open the LIHC breakdown →